De Novo Pharmaceuticals
De Novo Takes SkelGen to Japan
1st July 2011
CPhI in Osaka sees the Japanese launch of De Novo’s drug discovery software, SkelGen. “The development of a stand-alone platform and comprehensive remote technical support is a vital step in the globalisation of SkelGen’s appeal”, says Bill Harris, Head of Technical Support for De Novo.

Print this page

Recent News
De Novo Agrees Med Chem Synthesis Deal
De Novo Launches Academic Access Programme
De Novo Takes SkelGen to Japan
De Novo Launches ‘Stand-Alone; SkelGen
De Novo signs first academic licence with the University of Hertfordshire
De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes
De Novo Pharmaceuticals Ltd. Announces New Therapeutic Focus In the Area Of Metabolic Diseases And Appoints New Scientific Advisory Board.
De Novo Pharmaceuticals Ltd Announces Drug Discovery Collaboration Agreement with Genzyme
De Novo launches Reflex, a major upgrade to its in silico drug design platform